Study of the Effectiveness of Ozurdex for the Control of Uveitis
Status:
Completed
Trial end date:
2018-06-30
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate whether or not the dexamethasone pellet
(Ozurdex®, Allergan, Irvine, CA) can replace oral corticosteroid (e.g. prednisone) in the
treatment of active sight-threatening, noninfectious intermediate and/or posterior uveitis in
which immunosuppressive drug therapy is indicated.
Uveitis is an inflammation inside the eye. Uveitis can decrease patients' vision if it is not
treated.
The dexamethasone pellet is an implant filled with a corticosteroid medicine. This therapy is
approved by the Food and Drug Administration (FDA) for the treatment of intermediate and/or
posterior uveitis.
In this study investigators want to see if using the implant together with systemic
immunosuppressive drug therapy can result in lower ocular side effect profile but is
effective enough to replace the use of high-dose systemic corticosteroids in the treatment of
active intermediate and/or posterior uveitis. Knowing the effectiveness and safety of these
treatments is important because the kinds of uveitis being studied usually need to be treated
for many years. This information may help researchers understand uveitis better and may
suggest ways of improving treatment.
Adult patients with intermediate and/or posterior uveitis for which immunosuppressive drug
therapy with high-dose corticosteroid is planned may join.